Why and When to Use, and Next Steps
Joshua Beiner, MD
Department of Emergency Medicine (Pediatrics)
New York University Langone Medical Center
New York, NY
Matthew Lecuyer, MD
Department of Emergency Medicine (Pediatrics)
Warren Alpert Medical School of Brown University
Providence, RI
The Westley Croup Score was designed to track changes in the presentation of croup over time and is primarily used in research studies. Croup remains a clinical diagnosis, with the hallmark symptoms of barky cough and hoarse voice, with or without stridor.
The methodology for the original and follow-up validation studies (Klassen 1999; Super et al 1989) was rigorous. Both studies were prospective double-blind, randomized, placebo-controlled trials using a stringent definition of croup, and excluded the most mild or short-lived cases through pre-enrollment standardized mist therapy for all patients.
The primary outcome common to many treatment trials that used the Westley Croup Score was a positive clinical response, defined as a reduction in the score by 2 points, or return to a score of 0 or 1 point. Mild, moderate, and severe classifications and standardized treatments were studied and developed years later.
In the interrater reliability analysis performed by Super et al (1989), identical scores were found in 75% of the cases, while the remaining scores differed by only 1 point, for a weighted kappa of 0.75. Interrater reliability analysis in Klassen et al (1999) demonstrated a weighted kappa of 0.95 ± 0.02 among research assistants and primary investigators.
Since 1994, the score has been further validated and is the main scoring criteria used in the evaluation of a patient’s response to treatment in clinical trials. In 2011, a Cochrane Review performed a meta-analysis of studies that used glucocorticoids to treat croup. The review identified 41 trials of glucocorticoids versus placebo or any other treatment modality. The analysis showed a significant improvement in the Westley Croup Score for patients at 6 and 12 hours. The Westley Croup Score was considered a primary outcome. Secondary outcomes included length of stay and use of another treatment modality (Russell et al 2011).
Terry Klassen, MD
References
Original/Primary Reference
Validation
Other References
Copyright © MDCalc • Reprinted with permission.
Ashley Marchese, MD; Melissa L. Langhan, MD, MHS
November 2, 2017
December 31, 1969
4 AMA PRA Category 1 Credits™, 4 ACEP Category I Credits, 4 AAFP Prescribed Credits, 4 AOA Category 2-A or 2-B Credits. Specialty CME Credits: Included as part of the 4 credits, this CME activity is eligible for 0.5 Pharmacology CME credits